Page 301 - Programme book for The International Liver Congress 2015, EASL ILC 2015
P. 301
P1040 SHORT-TERM LOW-DOSE THIAZOLIDINEDIONES CAN ePOSTERS
BE A USEFUL BRIDGING THERAPY IN NASH PATIENTS
TOP 10% WITHOUT SIDE EFFECTS
YI P1041 Sanghoon Park*, Myungseok Lee, In Ho Moh, Surin Shin, South Korea
TOP 10% RAPID IMPROVEMENT OF HEPATIC STEATOSIS AS
YI P1042 ASSESSED BY CONTROLLED ATTENUATION PARAMETER
AFTER A TWO WEEK PROTEIN-ENRICHED LOW-CALORIE
TOP 10% DIET (HEPAFAST)
YI P1043 Anita Arslanow*, Melanie Teutsch, Hardy Walle, Frank Lammert,
Caroline S. Stokes, Germany
TOP 10%
YI P1044 DEREGULATION OF DE NOVO LIPOGENESIS CAN BE
ASSOCIATED WITH LIVER DAMAGE IN PATIENTS WITH
NON ALCOHOLIC FATTY LIVER DISEASE
Chiara Rosso*, Chiara Saponaro, Lavinia Mezzabotta, Ester Vanni,
Roberto Gambino, Francesca Saba, Ramy Ibrahim Kamal Jouness,
Melania Gaggini, Emma Buzzigoli, Gian Paolo Caviglia,
Maria Lorena Abate, Federico Salomone, Antonina Smedile,
Mario Rizzetto, Maurizio Cassader, Amalia Gastaldelli,
Elisabetta Bugianesi, Italy
EXERCISE REDUCES LIVER FAT, VISCERAL FAT AND
CIRCULATING TRIGLYCERIDES, BUT NOT CIRCULATING
INFLAMMATORY MARKERS IN NON-ALCOHOLIC
STEATOHEPATITIS
David Houghton*, Christian Thoma, Kate Hallsworth,
Kieren G. Hollingsworth, Christopher P. Day, Quentin M. Anstee,
Michael I. Trenell, The United Kingdom
RANDOMISED, PLACEBO-CONTROLLED CLINICAL TRIAL:
LONG-TERM RESVERATROL TREATMENT FOR NON-
ALCOHOLIC FATTY LIVER DISEASE
Sara Heebøll*, Stephen Hamilton-Dutoit,Ylva K. Hellberg,
Hans Stødkilde-Jørgensen, Niels Jessen, Steen B. Pedersen,
Henning Grønbæk, Denmark
Vienna, Austria • April 22–26, 2015 301
BE A USEFUL BRIDGING THERAPY IN NASH PATIENTS
TOP 10% WITHOUT SIDE EFFECTS
YI P1041 Sanghoon Park*, Myungseok Lee, In Ho Moh, Surin Shin, South Korea
TOP 10% RAPID IMPROVEMENT OF HEPATIC STEATOSIS AS
YI P1042 ASSESSED BY CONTROLLED ATTENUATION PARAMETER
AFTER A TWO WEEK PROTEIN-ENRICHED LOW-CALORIE
TOP 10% DIET (HEPAFAST)
YI P1043 Anita Arslanow*, Melanie Teutsch, Hardy Walle, Frank Lammert,
Caroline S. Stokes, Germany
TOP 10%
YI P1044 DEREGULATION OF DE NOVO LIPOGENESIS CAN BE
ASSOCIATED WITH LIVER DAMAGE IN PATIENTS WITH
NON ALCOHOLIC FATTY LIVER DISEASE
Chiara Rosso*, Chiara Saponaro, Lavinia Mezzabotta, Ester Vanni,
Roberto Gambino, Francesca Saba, Ramy Ibrahim Kamal Jouness,
Melania Gaggini, Emma Buzzigoli, Gian Paolo Caviglia,
Maria Lorena Abate, Federico Salomone, Antonina Smedile,
Mario Rizzetto, Maurizio Cassader, Amalia Gastaldelli,
Elisabetta Bugianesi, Italy
EXERCISE REDUCES LIVER FAT, VISCERAL FAT AND
CIRCULATING TRIGLYCERIDES, BUT NOT CIRCULATING
INFLAMMATORY MARKERS IN NON-ALCOHOLIC
STEATOHEPATITIS
David Houghton*, Christian Thoma, Kate Hallsworth,
Kieren G. Hollingsworth, Christopher P. Day, Quentin M. Anstee,
Michael I. Trenell, The United Kingdom
RANDOMISED, PLACEBO-CONTROLLED CLINICAL TRIAL:
LONG-TERM RESVERATROL TREATMENT FOR NON-
ALCOHOLIC FATTY LIVER DISEASE
Sara Heebøll*, Stephen Hamilton-Dutoit,Ylva K. Hellberg,
Hans Stødkilde-Jørgensen, Niels Jessen, Steen B. Pedersen,
Henning Grønbæk, Denmark
Vienna, Austria • April 22–26, 2015 301
